English for Special Purposes

Pharmaceutical English

Pharmaceutical English for drug development, regulatory strategy, trials, safety, CMC, quality, labeling, medical affairs, access, and launch.

8 modules
56 field terms
Interactive practice

Printable Curriculum

Download the full materials

Instructor Guide Participant Workbook Dialogue Lab Jargon Guide

Web Practice Lab

Practice the decisions, not only the vocabulary

Use the activities below to rehearse how a professional in this field clarifies risk, pushes back, and turns pressure into a concrete next step.

Module Focus

Scenario Coach

Respond under pressure

Your professional response

Jargon Flashcard

Pushback Builder

Build a four-step response

Evidence or fact Risk or consequence Decision or next step

Dialogue Coach

Model line

Language notes

Progress

Practice checklist

I used at least two field terms accurately. I named the evidence or policy boundary. I gave a concrete next step. I avoided overpromising.

0 of 4 complete

Student PDF in Web Form

Module map

Open Participant Workbook PDF

Drug Development Strategy, Unmet Need, TPP, and Evidence Logic

Pharma conversations often fail when teams discuss activities before aligning on the patient population, unmet need, target product profile, evidence standard, regulatory path, and commercial reality.

Indication, MOA, TPP, IND

Regulatory Pathways, IND Readiness, NDA/BLA Strategy, and Agency Interaction

Regulatory language must be specific about what is known, what is proposed, what the agency is being asked to agree with, and what remains a sponsor risk.

NDA, BLA, Accelerated approval, Complete response letter

Clinical Trial Design, Protocols, GCP, and Operations

Clinical trial English requires protocol precision, ethical discipline, operational realism, and the ability to explain tradeoffs among scientific rigor, patient protection, site burden, enrollment, and data integrity.

Protocol, Randomization, Blinding, Control arm

Endpoints, Estimands, Statistics, Data Readouts, and Clinical Meaning

Data readouts can be technically correct but strategically misleading. Learners need language for statistical significance, clinical relevance, estimands, missing data, intercurrent events, multiplicity, subgroup findings, and uncertainty.

Informed consent, Protocol deviation, Risk-based monitoring, Data integrity

Pharmacovigilance, Safety Signals, Risk-Benefit, and Label Updates

Safety language must be calm, disciplined, and precise. Learners need to distinguish adverse event, adverse reaction, serious, severe, expected, unexpected, related, signal, and confirmed risk.

Primary endpoint, Secondary endpoint, Exploratory endpoint, Estimand

CMC, CGMP, Quality Events, Manufacturing, and Supply

Quality and manufacturing conversations require exact language because patient supply and product quality depend on documented control, not informal confidence.

Intercurrent event, P-value, Confidence interval, Sensitivity analysis

Labeling, Medical Affairs, Promotion Review, and Compliance Boundaries

Pharma communication is constrained by approved labeling, evidence quality, audience, intent, and compliance rules. Learners need language for scientific exchange and for saying no to risky claims.

AE, SAE, SUSAR, MedDRA

Market Access, RWE, Launch Readiness, Biosimilars, and Lifecycle Management

Approval is not the end of pharmaceutical strategy. Learners need language for evidence generation, payer value, access barriers, launch governance, real-world evidence, lifecycle plans, generics, biosimilars, and loss of exclusivity.

Case narrative, Signal detection, Risk-benefit, REMS

More EFSP Tracks